Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intensified first-line FOLFIRI + Erbitux for potentially resectable metastatic colorectal cancer
2007-000357-54Phase 2Active
- Sponsor
- CHU Grenoble Alpes
- Start
- Jun 2007
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cetuximab, irinotecan, fluorouracil, folinic acid in colorectal cancer (CRC), colon cancer, rectal cancer, sponsored by CHU Grenoble Alpes. Started Jun 2007; status: active.
02
Drugs
cetuximabirinotecanfluorouracilfolinic acid
03
Conditions
colorectal cancer (CRC)colon cancerrectal cancer
Beyond the preview
Go deeper on 2007-000357-54.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000357-54.